Literature DB >> 25028345

Leukocyte telomere length and late-life depression.

Roxanne Schaakxs1, Josine E Verhoeven1, Richard C Oude Voshaar2, Hannie C Comijs1, Brenda W J H Penninx3.   

Abstract

OBJECTIVE: Depressive disorders have been associated with increased risk for aging-related diseases, possibly as a consequence of accelerated cellular aging. Cellular aging, indexed by telomere length (TL) shortening, has been linked to depression in adults younger than 60 years; however, it remains unclear whether this is the case in late-life depression (age >60 years). The objective of this study was to assess differences in TL between persons with current late-life depression and never-depressed comparisons and to examine the association between characteristics of late-life depression and TL.
METHODS: In this cross-sectional study using the Netherlands Study of Depression in Older Persons, 355 persons with current late-life depression and 128 never-depressed comparisons, aged 60-93 years (mean age [SD]: 70.5 [7.4] years, 65% women), were recruited through primary care and mental healthcare. Late-life depression was established using a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-based structured psychiatric interview. Leukocyte TL, expressed in base pairs (bp), was determined in fasting blood samples by performing quantitative polymerase chain reaction.
RESULTS: Mean TL did not differ between depressed persons (bp [SD]: 5,035 [431]) and never-depressed (bp [SD]: 5,057 [729]) comparisons. Further, TL was not associated with severity, duration, and age at onset of depression; comorbid anxiety disorders; anxiety symptoms; apathy severity; antidepressant use; benzodiazepine use; cognitive functioning; and childhood trauma.
CONCLUSION: Late-life depression was not associated with increased cellular aging. This absent association, which contradicts observations in younger adults, may be due to the potential larger heterogenic nature of late-life depression and lifetime cumulative exposure to other TL-damaging factors, possibly overruling effects of late-life depression.
Copyright © 2015 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Late-life depression; cellular aging; telomere length; telomere shortening

Mesh:

Year:  2014        PMID: 25028345     DOI: 10.1016/j.jagp.2014.06.003

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  20 in total

Review 1.  The Association Between Psychiatric Disorders and Telomere Length: A Meta-Analysis Involving 14,827 Persons.

Authors:  Sabrina M Darrow; Josine E Verhoeven; Dóra Révész; Daniel Lindqvist; Brenda W J H Penninx; Kevin L Delucchi; Owen M Wolkowitz; Carol A Mathews
Journal:  Psychosom Med       Date:  2016-09       Impact factor: 4.312

2.  Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls.

Authors:  Naomi M Simon; Zandra E Walton; Eric Bui; Jennifer Prescott; Elizabeth Hoge; Aparna Keshaviah; Noah Schwarz; Taylor Dryman; Rebecca A Ojserkis; Benjamin Kovachy; David Mischoulon; John Worthington; Immaculata De Vivo; Maurizio Fava; Kwok-Kin Wong
Journal:  Psychoneuroendocrinology       Date:  2015-04-13       Impact factor: 4.905

Review 3.  Psychiatric disorders and leukocyte telomere length: Underlying mechanisms linking mental illness with cellular aging.

Authors:  Daniel Lindqvist; Elissa S Epel; Synthia H Mellon; Brenda W Penninx; Dóra Révész; Josine E Verhoeven; Victor I Reus; Jue Lin; Laura Mahan; Christina M Hough; Rebecca Rosser; F Saverio Bersani; Elizabeth H Blackburn; Owen M Wolkowitz
Journal:  Neurosci Biobehav Rev       Date:  2015-05-18       Impact factor: 8.989

4.  Discrimination, mental health, and leukocyte telomere length among African American men.

Authors:  David H Chae; Elissa S Epel; Amani M Nuru-Jeter; Karen D Lincoln; Robert Joseph Taylor; Jue Lin; Elizabeth H Blackburn; Stephen B Thomas
Journal:  Psychoneuroendocrinology       Date:  2015-09-05       Impact factor: 4.905

5.  Early life adversity and telomere length: a meta-analysis.

Authors:  K K Ridout; M Levandowski; S J Ridout; L Gantz; K Goonan; D Palermo; L H Price; A R Tyrka
Journal:  Mol Psychiatry       Date:  2017-03-21       Impact factor: 15.992

6.  The relation of telomere length at midlife to subsequent 20-year depression trajectories among women.

Authors:  Jennifer Cai Gillis; Shun-Chiao Chang; Wei Wang; Naomi M Simon; Sharon-Lise Normand; Bernard A Rosner; Deborah Blacker; Immaculata DeVivo; Olivia I Okereke
Journal:  Depress Anxiety       Date:  2019-04-08       Impact factor: 6.505

7.  Telomere length and its relationships with lifestyle and behavioural factors: variations by sex and race/ethnicity.

Authors:  Chirag M Vyas; Soshiro Ogata; Charles F Reynolds; David Mischoulon; Grace Chang; Nancy R Cook; JoAnn E Manson; Marta Crous-Bou; Immaculata De Vivo; Olivia I Okereke
Journal:  Age Ageing       Date:  2021-05-05       Impact factor: 10.668

8.  Leukocyte telomere length predicts SSRI response in major depressive disorder: A preliminary report.

Authors:  Christina M Hough; F Saverio Bersani; Synthia H Mellon; Elissa S Epel; Victor I Reus; Daniel Lindqvist; Jue Lin; Laura Mahan; Rebecca Rosser; Heather Burke; John Coetzee; J Craig Nelson; Elizabeth H Blackburn; Owen M Wolkowitz
Journal:  Mol Neuropsychiatry       Date:  2016-06-22

9.  Relation of long-term patterns in caregiving activity and depressive symptoms to telomere length in older women.

Authors:  Shun-Chiao Chang; Marta Crous-Bou; Jennifer Prescott; Bernard Rosner; Naomi M Simon; Wei Wang; Immaculata De Vivo; Olivia I Okereke
Journal:  Psychoneuroendocrinology       Date:  2018-01-09       Impact factor: 4.905

10.  Telomere length and early trauma in schizophrenia.

Authors:  Gabriella Riley; Mary Perrin; Leila M Vaez-Azizi; Eugene Ruby; Raymond R Goetz; Roberta Dracxler; Julie Walsh-Messinger; David L Keefe; Peter F Buckley; Philip R Szeszko; Dolores Malaspina
Journal:  Schizophr Res       Date:  2018-04-02       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.